Research Guides

CJC-1295 + Ipamorelin 10+10mg: Research Guide

By UK Peptide Lab Research Team•19 September 2026•5 min read

Key Takeaways

The vial pairs CJC-1295, a modified GHRH(1-29) analogue (CAS 863288-34-0, 3647.8 g/mol), with Ipamorelin, a selective ghrelin-receptor agonist (Aib-His-D-2-Nal-D-Phe-Lys-NH2, CAS 170851-70-4, 711.85 g/mol), at 10mg of each.
The two components act at different receptors, GHRH against GHS-R1a, converging on the same pituitary somatotroph; class-level synergy between the two receptor families was shown by Bowers et al. (J Clin Endocrinol Metab, 1990).
The 1:1 mass ratio is far from equimolar: roughly 14 µmol of ipamorelin to 2.7 µmol of CJC-1295. The 10+10mg vial doubles total mass to 20mg without changing that stoichiometry.
No controlled study of this specific blend has been published; the evidence is two single-agent literatures (Raun et al., Eur J Endocrinol, 1998; Teichman et al., J Clin Endocrinol Metab, 2006). Supplied for in-vitro laboratory research only.

What is the Blend?

The CJC-1295 + Ipamorelin 10+10mg vial co-lyophilises two growth hormone secretagogues from different receptor families. CJC-1295 is a modified GHRH(1-29) analogue (CAS 863288-34-0, 3647.8 g/mol) that signals at the GHRH receptor, while Ipamorelin is a pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2, CAS 170851-70-4, 711.85 g/mol) acting as a selective agonist at the ghrelin receptor GHS-R1a. One reconstitution puts both into solution at a fixed 1:1 mass ratio, which is far from equimolar: each vial holds roughly 14 µmol of ipamorelin against 2.7 µmol of CJC-1295, a five-fold molar excess on the ghrelin side.

Two Receptors, One Somatotroph

The scientific case for the pairing rests on receptor complementarity. The GHRH receptor drives somatotroph growth hormone synthesis, while GHS-R1a, cloned by Howard and colleagues (Science, 1996), engages a separate signalling cascade on the same cell. Co-stimulating the two converges on one output through different second messengers, and class-level work by Bowers and colleagues (J Clin Endocrinol Metab, 1990) showed a GHRP acting alongside GHRH produces a greater combined response than either alone. That synergy literature, not any blend-specific study, is the design rationale.

What the Evidence Shows

The two components carry their own literatures. Raun and colleagues (Eur J Endocrinol, 1998) characterised Ipamorelin as the first growth hormone secretagogue with selectivity for GH release approaching GHRH itself, without the ACTH and cortisol elevation seen with earlier GHRPs. On the CJC-1295 side, Teichman and colleagues (J Clin Endocrinol Metab, 2006) reported dose-dependent rises in plasma GH and IGF-I in healthy adults, and Gobburu and colleagues (Pharm Res, 1999) modelled ipamorelin pharmacokinetics in volunteers. The honest caveat: no controlled study of this exact blend exists, and combination claims trace to those separate single-agent papers.

The 10+10mg Presentation

The 10+10mg vial is the higher-mass format of the same blend, £59.99 for 20mg of total peptide. Doubling from 5+5mg doubles both sides of the 1:1 mass ratio, so molar stoichiometry is unchanged; what changes is logistics, one batch, one certificate and fewer reconstitutions across a replicate series. Current batch UKPL-9515, supplier-tested with per-component content verified, with the certificate published on the product page and independent third-party verification pending.

Handling and Honest Limits

Store lyophilised vials at -20°C and hold reconstituted solution at 2-8°C, using within roughly 4 weeks. Reconstitute with bacteriostatic water down the vial wall and swirl gently; never shake or vortex. Once reconstituted the components cannot be separated. This material is supplied for in-vitro laboratory research only, with no dosing information and no human-use claims; it holds no marketing authorisation in any jurisdiction.

Related Products

CJC-1295 + Ipamorelin CJC-1295 + Ipamorelin Ipamorelin Bacteriostatic Water

Disclaimer: This article is for research and educational purposes only. All information provided is not intended as medical advice. UK Peptide Lab products are not for human consumption and are sold strictly for laboratory research use only.

Frequently Asked Questions

What is CJC-1295 + Ipamorelin?

It is a pre-blended research vial holding CJC-1295, a modified GHRH(1-29) analogue (CAS 863288-34-0, 3647.8 g/mol), and Ipamorelin, a selective ghrelin-receptor agonist (CAS 170851-70-4, 711.85 g/mol), lyophilised together at 10mg of each. The two compounds act at different receptors on the same pituitary somatotroph, which is why the pairing is a standard two-receptor design in growth hormone release research. Supplied for in-vitro laboratory research only.

Does the 10+10mg vial differ from the 5+5mg blend?

Only in mass per vial. Both carry the same 1:1 mass ratio, which resolves to roughly 14 µmol of ipamorelin against 2.7 µmol of CJC-1295, so doubling to 10+10mg doubles both sides of that ratio and leaves the stoichiometry unchanged. The 10+10mg vial simply covers longer replicate series from one batch and one certificate.

Has the CJC-1295 and Ipamorelin blend itself been studied?

No controlled study of this specific blend has been published. The evidence base is two single-agent literatures, Raun and colleagues (Eur J Endocrinol, 1998) for ipamorelin's selectivity and Teichman and colleagues (J Clin Endocrinol Metab, 2006) for CJC-1295 pharmacology, plus class-level GHRH and GHRP synergy work by Bowers and colleagues (J Clin Endocrinol Metab, 1990). That is stated plainly rather than papered over.

References

[1] Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. J Clin Endocrinol Metab (2006). View →
[2] Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol (1998). View →
[3] Growth hormone (GH)-releasing peptide stimulates GH release in normal men and acts synergistically with GH-releasing hormone. J Clin Endocrinol Metab (1990). View →
[4] A receptor in pituitary and hypothalamus that functions in growth hormone release. Science (1996). View →
[5] Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in human volunteers. Pharm Res (1999). View →